APRIL 26th, NEW JERSEY:
Keeping in view, the recent expansion of the CMS Open Payments rule qordata rolls out major product updates to help compliance teams across the life sciences industry with their Federal and State Transparency Reporting according to the latest requirements.
Earlier this month, qordata rolled out the BETA version of the enhanced and upgraded Aggregate Spend Reporting tool. Version V2.1 caters to reporting requirements according to CMS Open Payments Final Rule 2020 which included major changes in terms of “Covered Recipients”. After this update, the data sources can now be mapped to the new CMS template as per the final rule’s updated requirements.
However, this version can also be used to access older reports in the previously accepted format.
qordata has also completed the necessary master data management with NPPES, VPL (Validated Physicians List), and NPPL (Non-Physician Practitioners List) databases.
Based on the aforementioned enhancements to the products, some new validation errors can also be observed, using the qordata Aggregate Spend solution now.
Mohammad Ovais, the CEO of qordata expressed his excitement upon this development and said:
“Each day my team and I sit down to work upon meaningful technology solutions that help life sciences compliance community and share their workload. I am very proud and happy to roll out this version of our product that completely caters to the requirements laid out by CMS Open Payments final rule. Looking forward to solving more compliance challenges through meaningful technology interventions”.
The qordata Aggregate Spend solution V2.1 is in the implementation phase and will shortly be followed by version V2.2 which is in progress.
With the V2.2 rolled out, users will be able to perform physician/non-physician verification, compile new reports as per updated requirements, and view analytics accordingly.
About qordata:
qordata is one of the leading technology solution providers within the life sciences compliance sphere. qordata’s technology solutions and services enable pharma, biotech, and device companies to make the most of their data by implementing data-driven decision-making across their business functions such as compliance and marketing.
